Heat Biologics CEO and Lead Director to Participate in German Investor Forums
Back to Newsroom
Mentioned in this Article

Heat Biologics CEO and Lead Director to Participate in German Investor Forums

Wednesday, August 7, 2019 11:15 AM
Share this article now
Topic:
Conferences

DURHAM, NC / ACCESSWIRE / August 7, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing therapies designed to activate a patient’s immune system against cancer, today announced that the Company’s CEO, Jeff Wolf, and Lead Director, Dr. John Prendergast, will host a series of investor forums and discussions across Germany on August 13-14, 2019. Heat management will meet with investors in Frankfurt, Dusseldorf, Stuttgart and Munich on the dates below.

Investors interested in attending can register by registering at https://www.heatbio.com/german-roadshow-meetings; or emailing [email protected]. Event details will be provided upon confirmation of registration.

City: Dusseldorf
Date: Tuesday, August 13th

Venue: Lunch Presentation
Time: 1:00 PM CET

City: Frankfurt
Date: Wednesday, August 13th

Venue: Dinner Presentation
Time: 6:30 PM CET

City: Stuttgart
Date: Wednesday, August 14th

Venue: Lunch Presentation
Time: 12:00 PM CET

City: Munich
Date: Wednesday, August 14th

Venue: Dinner Presentation
Time: 6:30 PM CET

Heat will also host a webinar for our German investors on Friday, August 9th at 4PM Central European Time / 11AM Eastern Time. The webinar will be archived on the Company’s website for 7 days and available at: https://www.heatbio.com/news-media/events.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform ("TCAP") produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We have reached the enrollment targets in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) and with Merck's pembrolizumab (Keytruda®), and expect to report additional results before the end of 2019. Pelican Therapeutics, Inc., a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. For more information, please visit www.heatbio.com.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017

[email protected]

SOURCE: Heat Biologics, Inc.

Heat Biologics, Inc.
Exchange:
Ticker:
NASDAQ
HTBX
$1.67
-8.7432
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: